David Pulido-Gomez

I obtained my PhD in Biochemistry and Molecular Biology at the Autonomous University of Barcelona.  During my early research years, I studied the innate immune system as a source of novel antibiotics, using the antimicrobial structural determinants of the human ribonucleases to develop new therapeutic agents.

After my PhD, I completed two postdoctoral positions at Imperial College London and the University of Oxford, where I expanded my knowledge and skills in the production of biologicals and their characterization via structural biology and biophysical methodologies.

After my second post-doctoral position I became a Senior Postdoctoral Scientist at the Jenner Institute, University of Oxford. My work focused in the identification of improved antigen targets within the blood-stage merozoite malaria parasite; and the development and production of structure-guided protein-based vaccines according to GMP standards for clinical evaluation.

Afterwards, I transition to become a Principal Scientist and Team leader at Oxford Biomedica PLC where I coordinated a multidisciplinary team of scientists for the program delivery of process development, scale up, tech transfer, GMP manufacturing and late-stage process characterization and validation activities supporting the clinical and commercial implementation of advanced cell and gene therapies.

Currently, I am the Global Chemistry, Manufacturing, and Controls (CMC) Lead at the Pandemic Sciences Institute (PSI), University of Oxford. As the Global CMC Lead, I am responsible for the overall operational leadership and financial control for the PSI’s strategic delivery of accelerating the manufacturing and clinical development of specific vaccines against priority pathogens and pathogen families e.g., for Nipah virus, Lassa fever, MERS, Rift Valley Fever, Crimean Congo Haemorrhagic Fever, Ebola and other filoviruses, and other viral families which could pose a threat to human health through outbreaks. The focus of my role is to devise, to build the capacity and to implement a risk-based CMC Regulatory strategy for the PSI’s vaccine portfolio working alongside our internal collaborators at the Oxford Vaccine Group (OVG), at the Paediatrics Department and the KEMRI-welcome, and the Jenner Institute at the Nuffield Department of Medicine; our global manufacturing partners; and regulatory authorities worldwide; to support the development of these vaccines through the clinical trial stages and up to licensure as well as in preparation for future outbreaks ensuring rapid vaccine supply in case of emergency.